At the Frontiers of Care: The Emerging Role of CGM in Improving Glycemic Control and Outcomes During Pregnancy

Pregnant women with diabetes often require strict glycemic control in order to reduce the possibility of both immediate and long-term maternal and fetal complications, including macrosomia, large or small for gestational age, C-section, neonatal hyperglycemia, and many more. Additional potential maternal complications, like hypoglycemia, retinopathy, ketoacidosis, and preeclampsia can also occur, often having significant consequences.

In this setting, the role of continuous glucose monitoring (CGM) is crucial to allow clinicians and patients to visualize and better understand the real-time variations in glucose levels and minimize the risk of these complications. During this webinar, experts review the utility of CGM during pregnancy, including its efficacy and safety, as well as practical pearls for integration to clinical care.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, nurses, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the guidelines and recommendations for the use of CGM during pregnancy
  • Interpret the latest evidence about the efficacy and safety of CGM in pregnancy
  • Identify practical steps to incorporate CGM in pregnant women with diabetes in order to improve glycemic control, as well as maternal and fetal outcomes
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
03/15/2022
Course expires: 
03/15/2023
Rating: 
0

Pam R. Taub, MD, FACC
Founder and Director of Step Family
Cardiac Rehabilitation
Professor of Medicine
UC San Diego Health System
San Diego, CA

Dr. Taub discloses the following: 

Consultant Fees: Amarin, Amgen, Bayer, Boehringer-Ingelheim, Esperion, Medtronic
Contracted Research: Applied Therapeutics
Stockholder: Epirum Bio

 

Carol J. Levy, MD, CDCES
Professor of Medicine and Obstetrics
Director Mount Sinai Diabetes Center and T1D Clinical Research
Icahn School of Medicine at Mount Sinai
New York, NY

Dr.  Levy discloses the following: 

Consultant: Dexcom
Contracted Research: Dexcom/Abbott Diabetes

 

Helen R. Murphy, MBBCh BAO, MD, FRACP
Professor of Medicine, University of East Anglia (UEA), Norwich UK
Honorary Consultant Physician, Cambridge
University NHS Hospital Trust, Cambridge,
UK and Norfolk & Norwich University NHS
Hospital Trust, Norwich, UK

Dr. Murphy discloses the following: 

Consultant: Advisory Board Medtronic
Speakers' Bureau: Dexcom, Medtronic

 

ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hour

EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Dexcom.

JOINT ACCREDITATION STATEMENT
    

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. 

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-22-086-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period March 15, 2022 through March 15, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For questions about the accreditation of this activity, please visit www.pimed.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.